Roche	**SIX-MONTHLY SUSAR REPORT** **No. 1062347**
Authors	Caroline Baya, Vineeta Malik, Ashita Chand
Reviewers	Juergen Sylvius Scheele, Sai Li, Neelam Sharma
Department	Product Development, Regulatory, Roche Products Ltd, Welwyn Garden City, AL7 1TW, UK
Medicinal Product	Mabthera®/ Rituximab/ RO0452294
Report Data	Blinded
Interval Covered by This Report	26 May 2014 to 17 November 2014 (inclusive)

SSR approval date: See last date in electronic signature manifestation below.

SSR approved by: See electronic signature manifestation below.

Name	**Reason for Signing**	**Date and Time** (UTC)
Arguinzoniz,Miguel	Associate Safety Science Cluster Head	10-Dec-2014 12:34:01

During the current review period, 26 May 2014 to 17 November 2014[1] (inclusive), the Sponsor identified 38 potential[2] Suspected Unexpected Serious Adverse Reactions (SUSARs) for rituximab and blinded rituximab. In addition, there was one non–company Investigational Medicinal Product (IMP) SUSAR and no potential non–company IMP blinded SUSARs in trials where rituximab is the primary IMP.

The reported SUSARs did not necessitate changes to the rituximab study documentation during the current reporting interval.

After review of the clinical details of the reported SUSARs, the Sponsor concludes that no changes to the conduct of the ongoing clinical trials with rituximab are warranted. Based on the information presented in this report, the benefit-risk assessment of the use of rituximab in the indications under investigation remains favorable.

[1] The Data Lock Point of the SSR was realigned to Data Lock Point of Development Safety Update Report and Periodic Benefit Risk Evaluation Report in 2014, for this reason the reporting period of the current SSR is 26 May 2014 to 17 November 2014; however this report is referred to as Six-Monthly SUSAR Report in the Title Page and the Core Report.

[2] In the appended line listing, AER No. 1441041 (PT: Acute Cholecystitis) and AER No. 1442240 (PT: Dehydration) appears twice under two different indications namely, B-cell lymphoma and Diffuse large B-cell lymphoma. In the safety database, both the indications were coded because the patients enrolled in study GO27878 (AER No 1442240) had both the indications; while patients enrolled in study ML28881 (AER No. 1441041) had either B-cell lymphoma or Diffuse large B-cell lymphoma. To avoid over reporting, the events of acute cholecystitis and dehydration have been counted only once as a SUSAR for rituximab.

1. INTRODUCTION

This is a Six-Monthly Suspected Unexpected Serious Adverse Reaction (SUSAR) (SSR 1062347) prepared for rituximab in accordance with the European Union (EU) Clinical Trials Directive [1] and 'CT-3' guidance [2]. This SSR covers the reporting interval from 26 May 2014 to 17 November 2014[1], inclusive.

Methodology used to prepare this report is described in Section 4.

2. ACTIONS TAKEN IN THE REPORTING INTERVAL RELATED TO REPORTED SUSARS

2.1 CHANGES TO REFERENCE SAFETY INFORMATION

The reference safety information (RSI) in effect at the start of the reporting interval, for autoimmune indications was the Investigator's Brochure (IB) version 13.0 dated May 2014 which incorporates the Developmental Core Safety Information (DCSI) version 5.0 dated June 2014, this RSI has been used as the reference document for the review period.

The IB for rituximab oncology intravenous, version 18.0 dated July 2013 which incorporated DCSI version 6.0 dated July 2013 was used as the safety reference document till July 2014. In July 2014, IB version 19.0 (containing Section 6 "Guidance For The Investigator (Reference Safety Information)") became available and was used as the safety reference document for the remaining review period.

The IB for rituximab subcutaneous formulation, version 5.0 dated February 2014 which incorporates DCSI version 7.0 dated February 2014, was used as the safety reference document for the review period.

The reported SUSARs did not necessitate changes to the rituximab IB and DCSI during the current reporting interval.

Prior to 1 April 2014, the Sponsor also used the rituximab Core Data Sheet dated November 2013 in effect at the start of the reporting interval as the RSI in trials where the Investigators use local label as the safety reference document. From 1 April 2014, the company uses rituximab EU Summary of Product Characteristics (SPC) to assess event listedness in such trials.

[1] The Data Lock Point of the SSR was realigned to Data Lock Point of Development Safety Update Report and Periodic Benefit Risk Evaluation Report in 2014, for this reason the reporting period of the current SSR is 26 May 2014 to 17 November 2014; however this report is referred to as Six-Monthly SUSAR Report in the Title Page and the Core Report.

The following documents were used as the RSI for non-company Investigational Medicinal Product (IMP) SUSARs during the review interval:

- Bendamustine EU SPC was used to determine SUSARs to bendamustine

2.2 CHANGES TO OTHER STUDY DOCUMENTATION

The reported SUSARs did not necessitate changes to other study documentation for rituximab during the current reporting period.

3. CONCLUSION

After review of the clinical details of the reported SUSARs, the Sponsor concludes that no changes to the conduct of the ongoing clinical trials with rituximab are warranted. Based on the information presented in this report, the benefit-risk assessment of the use of rituximab in the indications under investigation remains favorable.

4. METHODOLOGY

4.1 CASE INCLUSION

This report includes a line listing[2] of all SUSAR cases submitted to the Investigators in the six-monthly reporting period outlined in Section 1, for a given Roche IMP (hereinafter referred to as the SSR drug), and/or any non-Roche IMPs used in clinical trials where the SSR drug is the primary IMP.

Roche expedites all initial SUSAR cases to the Investigators. In addition, follow-up SUSAR cases are submitted to the Investigators if a change in event seriousness, causality, preferred term, or expectedness for safety reference document occurs, or an additional (existing or new) event in the case qualifies for a SUSAR.

If two or more SUSAR case versions are submitted during the reporting period, only the version most recently submitted during the reporting period is presented in the report. SUSAR cases submitted during the reporting period that no longer qualify for a SUSAR in the most recently submitted version, or were logically deleted subsequent to submission, are not presented in the report.

---

[2] In the appended line listing, AER No. 1441041 (PT: Acute Cholecystitis) and AER No. 1442240 (PT: Dehydration) appears twice under two different indications namely, B-cell lymphoma and Diffuse large B-cell lymphoma. In the safety database, both the indications were coded because the patients enrolled in study GO27878 (AER No 1442240) had both the indications; while patients enrolled in study ML28881 (AER No. 1441041) had either B-cell lymphoma or Diffuse large B-cell lymphoma. To avoid over reporting, the events of acute cholecystitis and dehydration have been counted only once as a SUSAR for rituximab.

4.2 LISTING PRESENTATION

The version of Medical Dictionary for Regulatory Activities used to generate the line listing is printed in the listing.

The line listing is sorted by indication coded by Medical Dictionary for Regulatory Activities preferred term. Under each indication, the reports are shown under two different sub-sections: “SUSARs” and “SUSARs to Other IMPs and Comparators”. Separate tables are produced for each indication.

If more than one indication is investigated in a study (e.g., refractory solid tumors or lymphoma) and the indication is not provided by the reporter, the company initially codes all study indications in the case. As a result, such a case appears in more than one indication table. This is taken into consideration when counting SUSARs to prevent over count.

All IMPs for which the event is a SUSAR are shown in bold – for the SSR drug and other Roche IMPs in the “SUSARs” table, and for non-Roche IMPs, in trials where the SSR drug is the primary IMP, in the “SUSARs to Other IMPs and Comparators” table. If the suspect medication column contains more than one SUSAR drug, then each SUSAR event is marked with the list of drug sequence numbers to which it is related.

Only SUSARs to the SSR drug and non-Roche IMPs in trials where the SSR drug is the primary IMP are counted in this report, because SUSARs to other Roche IMPs are counted in their respective SSRs.

Events in a SUSAR case that do not qualify for a SUSAR are not presented in the report.

4.3 CAUSALITY ASSESSMENT

Both the reporter and the company causality assessments are shown for each SUSAR. Roche’s medical assessment of causality is based on the information provided in the individual case safety report. This assessment does not represent a full evaluation of all similar cases and epidemiological data of the therapeutic population. The company assessment of causal relationship at the event level, within the safety database, is not intended to suggest, imply, or confirm the event in question is a reaction to the medicinal product. Rather this assessment fulfills a regulatory requirement to indicate a potential association between product and event.

Adverse events where the causal relationship to the IMP is assessed by the reporter, or the company, as unknown will be considered by Roche to be suspected adverse reactions for reporting purposes, and thus submitted to Investigators if meeting other SUSAR criteria. Submission of adverse events

where the causal relationship to the IMP is not provided by the reporter is driven by the company causality assessment.

4.4 REFERENCE SAFETY INFORMATION

For rituximab, for autoimmune indications and subcutaneous formulation, the RSI was primarily the IB, which incorporates the DCSI. The DCSI details which events are to be considered expected.

For rituximab, oncology intravenous, the RSI was primarily the IB, which detailed those events that are to be considered expected. RSI will be updated with only those events evaluated by the Sponsor and preliminarily identified as suspected Adverse Drug Reactions.

From 1 April 2014, the company uses EU SPC to assess event listedness in trials where the Investigators use local label as the reference safety document. Prior to this date, Core Data Sheet was used for this assessment.

The reference safety document for non-Roche IMPs is the EU SPC (or United Kingdom SPC if an EU SPC is not available), or the IB, as defined in the respective study protocols.

Expectedness (or listedness) for each SUSAR is determined based on reference safety document version in effect at the time of case entry.

5. REFERENCES

1. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use
2. Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use (‘CT-3’) (2011/C 172/01)

RITUXIMAB

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
BO21223 1069368(8.0) 2010-024132-41 209358 56556 GERMANY 73 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x---- / 3 Weeks	06MAR2012/ --	Hypertension Duodenal ulcer Dyspepsia Blood uric acid increased Vomiting Constipation Bone pain Osteoporosis Hyperlipidaemia Herpes zoster	LUMBAR SPINE FRACTURES Lumbar vertebral fracture (09MAY2012)	Related Related EU-SPC Not recovered/not resolved
	2 CYCLOPHOSPHAMIDE	Intravenous (not otherwise specified) 1x---- / 3 Weeks	06MAR2012/ --			
	3 DOXORUBICIN	Intravenous (not otherwise specified) 1x---- / 3 Weeks	06MAR2012/ --			
	4 VINCRISTINE	Intravenous bolus 1x---- / 3 Weeks	06MAR2012/ --			
	5 PREDNISONE	Oral 1x---- / 3 Weeks	07MAR2012/ --			

RITUXIMAB

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
BO21223 1338066(10.0) 2010-024132-41 208744 53980 UNITED KINGDOM 70 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x---- / 2 Months	01MAY2013/ --	Hypertension Gastrooesophageal reflux disease	HEMOPHAGOCYTIC SYNDROME Histiocytosis haematophagic (16FEB2014)	Related Related CDS Not recovered/not resolved
	2 BENDAMUSTINE	Intravenous (not otherwise specified) 1x---- / 4 Weeks	01MAY2013/ --			
ML28881 1418431(1.0) 2013-000647-12 258946 2589461741 ITALY 56 Years Male	**1 # RITUXIMAB**	Subcutaneous 1x1400mg / 2 Months	21MAY2014/ --		SUSPECTED MYOCARDITIS Myocarditis (23MAY2014)	Related Related IB Unknown
ML28881 1441041(0.0) 2013-000647-12 259187 2591871404 ITALY -- Female	**1 # RITUXIMAB**	Subcutaneous 1x1400mg / 21 Days	11JUL2014/ --	Cholelithiasis	ACUTE CHOLECYSTITIS Cholecystitis acute (--)	Related Related IB Not recovered/not resolved

RITUXIMAB

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
GO27878 1442240(0.0) 2013-003749-40 271875 10001 USA 79 Years Male	**1 # GDC-0199 (BCL-2 SELECTIVE INHIBITOR)**	Unknown 1x200Unit Not Reported / 1 Days	12JUN2014/ --	Hypertension Type 2 diabetes mellitus Hypercholesterolaemia Glaucoma Gout Productive cough Vertigo	DEHYDRATION Dehydration [SUSAR Drugs 1, 2] (27JUL2014)	Related Not Related IB/EU-SPC Not recovered/not resolved
	2 # RITUXIMAB	Unknown 1x780Unit Not Reported / 21 Days	09JUN2014/ --			
	3 CYCLOPHOSPHAMIDE	Unknown 1x1463Unit Not Reported / 21 Days	09JUN2014/ --			
	4 DOXORUBICIN	Unknown 1x98Unit Not Reported / 21 Days	09JUN2014/ --			
	5 VINCRISTINE	Unknown 1x2Unit Not Reported / 21 Days	09JUN2014/ --			
	6 PREDNISONE	Unknown --x100Unit Not Reported / -- --	09JUN2014/ --			

RITUXIMAB

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
ML28881 1442982(1.0) 2013-000647-12 258390 2583901346 ITALY 71 Years Female	**1 # RITUXIMAB**	Subcutaneous 1x1400mg / 3 Weeks	22JUL2014/ --	Hypertension	HYPOKALEMIA Hypokalaemia (28JUL2014)	Related Not Related IB Not recovered/not resolved
	2 CYCLOPHOSPHAMIDE	Unknown --	-- --			
	3 DOXORUBICIN	Unknown --	-- --			
	4 VINCRISTINE	Unknown --	-- --			
	5 PREDNISONE	Unknown --	-- --			
MO25455 1459930(5.0) 2010-023407-95 209731 209731005 AUSTRIA 58 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) --x630mg / -- --	13MAR2013/ --		SEPTIC SHOCK Septic shock [SUSAR Drugs 1, 2] (05SEP2014) PERIMYOCARDITIS Myocarditis [SUSAR Drugs 1, 2] (05SEP2014)	Related Related IB Fatal Related Related IB Fatal

RITUXIMAB

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
	2 # RITUXIMAB	Subcutaneous --x1400mg / -- -- Subcutaneous --x1400mg / -- -- Subcutaneous --x1400mg / -- -- Subcutaneous --x1400mg / -- -- Subcutaneous --x1400mg / -- -- Subcutaneous --x1400mg / -- -- Subcutaneous --x1400mg / -- -- Subcutaneous --x1400mg / -- -- Subcutaneous --x1400mg / -- -- Subcutaneous --x1400mg / -- -- Subcutaneous --x1400mg / -- --	10APR2013/ -- 07MAY2013/ -- 04JUN2013/ -- 02JUL2013/ -- 02SEP2013/ -- 30SEP2013/ -- 17DEC2013/ -- 28OCT2013/ -- 18FEB2014/ -- 10APR2014/ -- 05JUN2014/ -- 05AUG2014/ 05SEP2014			

RITUXIMAB

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO28457 1464246(0.0) 2012-003230-17 256280 256280011 GUATEMALA 59 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x596mg / 3 Weeks	28MAY2014/ --	Hypertension	BRONCHOPNEUMONIA Bronchopneumonia [SUSAR Drugs 1, 2] (07SEP2014)	Related Related IB Fatal
	2 # RITUXIMAB	Subcutaneous 1x1400mg / 3 Weeks	--/ 27AUG2014			
	3 CYCLOPHOSPHAMIDE	Unknown --	-- --			
	4 DOXORUBICIN	Unknown --	-- --			
	5 VINCRISTINE	Unknown --	-- --			
	6 PREDNISONE	Unknown --	-- --			

RITUXIMAB

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
ML21685 720642(2.0) 2008-005859-16 242 71242 GERMANY 76 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x671mg / 4 Weeks	15JUL2010/ --	Neoplasm progression Non-Hodgkin's lymphoma	MULTIPLE ORGAN FAILURE Multi-organ failure (12DEC2010)	Related Related EU-SPC Fatal
	2 DEXAMETHASONE	Unknown --	-- --			
	3 CYCLOPHOSPHAMIDE	Unknown --	30SEP2010/ 06DEC2010			
	4 DOXORUBICIN	Unknown --	30SEP2010/ 06DEC2010			
	5 VINCRISTINE	Unknown --	30SEP2010/ 06DEC2010			
	6 PREDNISOLONE	Unknown --	30SEP2010/ 06DEC2010			
	7 BENDAMUSTINE	Intravenous (not otherwise specified) 1x322mg / 4 Weeks	17JUL2010/ --			

Indication: B-CELL LYMPHOMA - SUSARs to non-company IMPs

NO SUSARS WERE IDENTIFIED

RITUXIMAB

Indication: CHRONIC GRAFT VERSUS HOST DISEASE - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
ML19922 1436013(0.0) 2008-004125-42 -- 37 NETHERLANDS 52 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x375mg/m2 / 1 Week	20MAY2014/ 11JUN2014	B-cell lymphoma Stem cell transplant Stem cell transplant	HYPERBILIRUBINEMIA Hyperbilirubinaemia (14JUL2014)	Related Related IB Not Reported
					POSSIBLE PANCREATITIS Pancreatitis (14JUL2014)	Related Related IB Not Reported
	2 NILOTINIB HYDROCHLORIDE	Oral 2x300mg / 1 Days	03JUL2014/ 14JUL2014			

Indication: CHRONIC GRAFT VERSUS HOST DISEASE - SUSARs to non-company IMPs

NO SUSARS WERE IDENTIFIED

RITUXIMAB

Indication: CHRONIC LYMPHOCYTIC LEUKAEMIA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
ML21135 GNE311492(6.0) 2007-002733-36 117679 403 SPAIN 71 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x375mg/m2 / 2 Months	11FEB2009/ 12NOV2010	Diarrhoea	BAD ABSORPTION SYNDROME Malabsorption (29OCT2010)	Related Related IB Fatal
	2 FLUDARABINE PHOSPHATE	Intravenous (not otherwise specified) --x25mg/m2 / -- --	11FEB2009/ --			
	3 CYCLOPHOSPHAMIDE	Intravenous (not otherwise specified) 1x---- / 1 Months	11FEB2009/ --			

Indication: CHRONIC LYMPHOCYTIC LEUKAEMIA - SUSARs to non-company IMPs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO22468 1438734(0.0) 2009-012072-28 168630 16863006 TUNISIA 52 Years Female	1 RITUXIMAB	Intravenous (not otherwise specified) 1x771mg / 1 Months	08DEC2011/ --		GASTRIC CARCINOMA Gastric cancer (27JUN2014)	Related Related EU-SPC Unknown
	2 # **BENDAMUSTINE**	Intravenous (not otherwise specified) 1x276mg / 1 Months	08DEC2011/ --			

RITUXIMAB

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO28457 1312423(6.0) 2012-003230-17 252540 252540001 MALAYSIA 49 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x611mg / 21 Days Intravenous (not otherwise specified) 1x375mg/m2 / 21 Days	28SEP2013/ -- 08NOV2013/ --	Autoimmune haemolytic anaemia Neutropenia Anaemia	RITUXIMAB INDUCED PNEUMONITIS Pneumonitis (29NOV2013) LONG SEGMENT THROMBOSIS AT LEFT BRACHIAL VEIN Venous thrombosis limb (09OCT2013)	Related Related IB Fatal Related Related IB Fatal
	2 CYCLOPHOSPHAMIDE	Unknown --	-- --			
	3 DOXORUBICIN	Unknown --	-- --			
	4 VINCRISTINE	Unknown --	-- --			
	5 PREDNISONE	Unknown --	-- --			

RITUXIMAB

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO28107 1346175(6.0) 2012-000669-19 250930 250930006 FRANCE 76 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) --x375mg/m2 / -- --	-- --	Polymyalgia rheumatica Osteoarthritis Dizziness Asthenia Weight decreased Bone pain Splenomegaly Appendicectomy Joint prosthesis user	DETERIORATION OF HEALTH STATUS General physical health deterioration [SUSAR Drugs 1, 2] (14FEB2014)	Related Related IB Recovered/resolved with se (14MAR2014)
	2 # RITUXIMAB	Subcutaneous --x1400mg / -- --	11OCT2013/ --			
		Subcutaneous --x1400mg / -- --	06FEB2014/ --			
	3 CYCLOPHOSPHAMIDE	Intravenous (not otherwise specified) --	-- --			
	4 DOXORUBICIN	Intravenous (not otherwise specified) --	-- --			
	5 VINCRISTINE	Intravenous (not otherwise specified) --	-- --			
	6 PREDNISONE	Intravenous (not otherwise specified) --	-- --			

RITUXIMAB

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO28107 1368631(8.0) 2012-000669-19 248977 248977001 PORTUGAL 74 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x675mg / 21 Days	10MAR2014/ --	Chronic obstructive pulmonary disease Type 2 diabetes mellitus Appendicectomy Tobacco user Biopsy lymph gland Biopsy bone marrow	DECOMPENSATED DIABETES MELLITUS Diabetes mellitus (17MAR2014)	Related Not Related IB Recovered/resolved (24MAR2014)
	2 CYCLOPHOSPHAMIDE	Unknown 1x1350mg / 21 Days	10MAR2014/ --			
	3 DOXORUBICIN	Unknown 1x90mg / 21 Days	10MAR2014/ --			
	4 VINCRISTINE	Unknown 1x2mg / 21 Days	10MAR2014/ --			
	5 PREDNISOLONE	Unknown 1x100mg / 21 Days	10MAR2014/ --			

RITUXIMAB

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
BO21005 1371288(2.0) 2010-024194-39 254942 21051 RUSSIAN FEDERATION 66 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x---- / 3 Weeks	05DEC2013/ --	Haemorrhoids Duodenal ulcer Oedema peripheral	ACUTE TOXIC DRUG ASSOCIATED ENCEPHALOPATHY Toxic encephalopathy (19MAR2014)	Related Related EU-SPC Fatal
	2 CYCLOPHOSPHAMIDE	Intravenous (not otherwise specified) 1x---- / 3 Weeks	06DEC2013/ --			
	3 DOXORUBICIN	Intravenous (not otherwise specified) 1x---- / 3 Weeks	06DEC2013/ --			
	4 VINCRISTINE	Intravenous drip 1x---- / 3 Weeks	06DEC2013/ --			
	5 PREDNISONE	Unknown 1x---- / 3 Weeks	06DEC2013/ --			

RITUXIMAB

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO28457 1410767(3.0) 2012-003230-17 254294 254294005 BRAZIL 55 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x701.25mg / 3 Weeks	21MAY2014/ --	Constipation Hypertension Spinal pain	SEPTIC SHOCK Septic shock (27MAY2014)	Related Related IB Fatal
	2 CYCLOPHOSPHAMIDE	Unknown --	-- --			
	3 DOXORUBICIN	Unknown --	-- --			
	4 PREDNISOLONE	Unknown --	-- --			
	5 VINCRISTINE	Unknown --	-- --			

RITUXIMAB

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
BO21005 1413180(0.0) 2010-024194-39 257528 19904 JAPAN 77 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x---- / 3 Weeks	03MAR2014/ --	Constipation Dementia with Lewy bodies Osteoporosis Spinal compression fracture Osteoporosis	MELENA Melaena (02JUN2014)	Related Related EU-SPC Not recovered/not resolved
	2 CYCLOPHOSPHAMIDE	Intravenous (not otherwise specified) 1x---- / 3 Weeks	04MAR2014/ --			
	3 DOXORUBICIN	Intravenous (not otherwise specified) 1x---- / 3 Weeks	04MAR2014/ --			
	4 VINCRISTINE	Intravenous (not otherwise specified) 1x---- / 3 Weeks	04MAR2014/ --			
	5 PREDNISOLONE	Oral 1x---- / 3 Weeks	03MAR2014/ --			

RITUXIMAB

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO28457 1417171(3.0) 2012-003230-17 257289 257289017 INDONESIA 68 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) --	-- --		SUDDEN HEART ATTACK Myocardial infarction [SUSAR Drugs 1, 2] (09JUN2014)	Related Related IB Fatal
	2 # RITUXIMAB	Subcutaneous 1x1400mg / 3 Weeks	04MAR2014/ --			
	3 FLUCONAZOLE	Oral 2x50mg / 1 Days	03JUN2014/ --			

RITUXIMAB

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO28457 1423467(3.0) 2012-003230-17 256788 256788007 GERMANY 80 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) --x630mg / -- -- Intravenous (not otherwise specified) --x630mg / -- -- Intravenous (not otherwise specified) --x630mg / -- -- Intravenous (not otherwise specified) --x630mg / -- --	13MAY2014/ -- 27MAY2014/ -- 10JUN2014/ -- 01JUL2014/ --	Diabetes mellitus Atrial fibrillation Hypertension Guillain-Barre syndrome Leukopenia	HYPERTHYREOSIS Hyperthyroidism (18JUN2014)	Related Related IB Not recovered/not resolved
	2 CYCLOPHOSPHAMIDE	Unknown --	-- --			
	3 DOXORUBICIN	Unknown --	-- --			
	4 VINCRISTINE	Unknown --	-- --			
	5 PREDNISONE	Unknown --	-- --			
ML28881 1441041(0.0) 2013-000647-12 259187 2591871404 ITALY -- Female	**1 # RITUXIMAB**	Subcutaneous 1x1400mg / 21 Days	11JUL2014/ --	Cholelithiasis	ACUTE CHOLECYSTITIS Cholecystitis acute (--)	Related Related IB Not recovered/not resolved

RITUXIMAB

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
GO27878 1442240(0.0) 2013-003749-40 271875 10001 USA 79 Years Male	**1 # GDC-0199 (BCL-2 SELECTIVE INHIBITOR)**	Unknown 1x200Unit Not Reported / 1 Days	12JUN2014/ --	Hypertension Type 2 diabetes mellitus Hypercholesterolaemia Glaucoma Gout Productive cough Vertigo	DEHYDRATION Dehydration [SUSAR Drugs 1, 2] (27JUL2014)	Related Not Related IB/EU-SPC Not recovered/not resolved
	2 # RITUXIMAB	Unknown 1x780Unit Not Reported / 21 Days	09JUN2014/ --			
	3 CYCLOPHOSPHAMIDE	Unknown 1x1463Unit Not Reported / 21 Days	09JUN2014/ --			
	4 DOXORUBICIN	Unknown 1x98Unit Not Reported / 21 Days	09JUN2014/ --			
	5 VINCRISTINE	Unknown 1x2Unit Not Reported / 21 Days	09JUN2014/ --			
	6 PREDNISONE	Unknown --x100Unit Not Reported / -- --	09JUN2014/ --			

RITUXIMAB

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
BO21005 1443612(0.0) 2010-024194-39 210504 20102 MEXICO 75 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x---- / 3 Weeks	18FEB2014/ --	Type 2 diabetes mellitus	ACUTE RESPIRATORY FAILURE Acute respiratory failure (10JUL2014)	Related Related EU-SPC Fatal
	2 CYCLOPHOSPHAMIDE	Intravenous (not otherwise specified) 1x---- / 3 Weeks	18FEB2014/ --			
	3 DOXORUBICIN	Intravenous (not otherwise specified) 1x---- / 3 Weeks	18FEB2014/ --			
	4 VINCRISTINE	Intravenous bolus 1x---- / 3 Weeks	18FEB2014/ --			
	5 PREDNISOLONE	Oral 1x---- / 3 Weeks	18FEB2013/ --			

RITUXIMAB

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
BO21005 1452322(1.0) 2010-024194-39 251856 20652 POLAND 72 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x---- / 3 Weeks	10FEB2014/ --	Hypertension Neutropenia Breast cancer	EASY FATIGUE Fatigue (19AUG2014) EMESIS Vomiting (19AUG2014)	Related Related EU-SPC Fatal Related Related EU-SPC Fatal
	2 CYCLOPHOSPHAMIDE	Intravenous (not otherwise specified) 1x---- / 3 Weeks	10FEB2014/ --			
	3 DOXORUBICIN	Intravenous (not otherwise specified) 1x---- / 3 Weeks	10FEB2014/ --			
	4 VINCRISTINE	Intravenous bolus 1x---- / 3 Weeks	10FEB2014/ --			
	5 PREDNISONE	Oral 1x---- / 3 Weeks	10FEB2014/ --			

RITUXIMAB

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO28457 1458581(7.0) 2012-003230-17 253073 253073008 BRAZIL 40 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x375mg/m2 / 21 Days Intravenous (not otherwise specified) 1x375mg/m2 / 21 Days	17JUN2014/ -- 30SEP2014/ --	Headache	DIABETES INSIPIDUS Diabetes insipidus [SUSAR Drugs 1, 2] (08SEP2014)	Related Not Related IB Recovered/resolved (29SEP2014)
	2 # RITUXIMAB	Subcutaneous 1x1400mg / 21 Days	-- --			
	3 VINCRISTINE	Unknown --	-- --			
	4 CYCLOPHOSPHAMIDE	Unknown --	-- --			
	5 DOXORUBICIN	Unknown --	-- --			
	6 PREDNISOLONE	Unknown --	-- --			

RITUXIMAB

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
ML28881 1464934(0.0) 2013-000647-12 258260 2582601303 ITALY 61 Years Male	**1 # RITUXIMAB**	Subcutaneous 1x1400mg / 21 Days	13AUG2014/ --		PLEURAL EFFUSION Pleural effusion (09SEP2014)	Related Related IB Not recovered/not resolved
	2 CYCLOPHOSPHAMIDE	Unknown --	-- -- --			
	3 DOXORUBICIN	Unknown --	-- -- --			
	4 VINCRISTINE SULFATE	Unknown --	-- -- --			
	5 PREDNISONE	Unknown --x25mg / -- -- Unknown --x12.5mg / -- --	09SEP2014/ 09SEP2014 10SEP2014/ 10SEP2014			

RITUXIMAB

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO28107 1468120(4.0) 2012-000669-19 250179 250179003 RUSSIAN FEDERATION 63 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) --	-- --		BILATERAL PNEUMONIA Pneumonia [SUSAR Drugs 1, 2] (25SEP2014)	Related Related IB Fatal
	2 # RITUXIMAB	Subcutaneous --x1400mg / -- --	22APR2014/ --			
	3 CYCLOPHOSPHAMIDE	Unknown --	-- --			
	4 DOXORUBICIN	Unknown --	-- --			
	5 VINCRISTINE	Unknown --	-- --			
	6 PREDNISONE	Unknown --	-- --			

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs to non-company IMPs

NO SUSARS WERE IDENTIFIED

RITUXIMAB

Indication: LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
ML28943 1409124(2.0) 2013-001118-14 261812 2618120285 SPAIN 71 Years Male	**1 # RITUXIMAB**	Subcutaneous 1x1400mg / 2 Months	19FEB2014/ --	Type 2 diabetes mellitus Pancreatitis chronic Peripheral arterial occlusive disease Vascular encephalopathy Diabetic retinopathy Hypertension Bronchitis chronic Mesenteric panniculitis	SEPSIS Sepsis (26MAY2014)	Related Related IB Fatal

Indication: LYMPHOMA - SUSARs to non-company IMPs

NO SUSARS WERE IDENTIFIED

RITUXIMAB

Indication: LYMPHOPLASMACYTOID LYMPHOMA/IMMUNOCYTOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
ML21685 1490497(0.0) 2008-005859-16 217 72166 GERMANY 61 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x680mg / 4 Weeks	15OCT2012/ 27AUG2013		TOXIC ENCEPHALOPATHY Toxic encephalopathy (NOV2013)	Related Related EU-SPC Fatal
	2 BENDAMUSTINE	Intravenous (not otherwise specified) --x160mg / -- --	18OCT2012/ 15FEB2013			
	3 CYCLOPHOSPHAMIDE	Unknown --	-- --			
	4 FLUDARABINE PHOSPHATE	Unknown --	-- --			

Indication: LYMPHOPLASMACYTOID LYMPHOMA/IMMUNOCYTOMA - SUSARs to non-company IMPs

NO SUSARS WERE IDENTIFIED

RITUXIMAB

Indication: MALIGNANT LYMPHOID NEOPLASM - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
ML19922 1413221(4.0) 2008-004125-42 -- 35 NETHERLANDS 48 Years Male	**1 # RITUXIMAB**	Unknown --x375mg/m2 / -- -- Unknown --x375mg/m2 / -- -- Unknown --x375mg/m2 / -- -- Unknown --x375mg/m2 / -- --	19FEB2014/ -- 26FEB2014/ -- 06MAR2014/ -- 14MAR2014/ --	Leukaemia Non-Hodgkin's lymphoma Stem cell transplant Chronic graft versus host disease	BONE INFECTION Osteomyelitis (--)	Related Related IB Fatal
ML19922 1428435(2.0) 2008-004125-42 -- 27 NETHERLANDS 66 Years Male	**1 # RITUXIMAB**	Unknown --x375mg/m2 / 1 Weeks Unknown --x375mg/m2 / 1 Weeks Unknown --x375mg/m2 / 1 Weeks Unknown --x375mg/m2 / 1 Weeks	03JUL2013/ -- 10JUL2013/ -- 17JUL2013/ -- 24JUL2013/ --	Plasma cell myeloma Atrial fibrillation Stem cell transplant Pneumonia	HAEMOPTYSIS Haemoptysis (28JUN2014)	Related Related IB Not Reported

Indication: MALIGNANT LYMPHOID NEOPLASM - SUSARs to non-company IMPs

NO SUSARS WERE IDENTIFIED

RITUXIMAB

Indication: MANTLE CELL LYMPHOMA STAGE IV - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO17244 1469149(1.0) EVCT-999999-25 417 239 GERMANY 74 Years Male	**1 # RITUXIMAB**	Unknown --x680mg / -- --	18JUN2014/ --	Chronic gastritis Anaemia	ABDOMINAL COMPLAINTS (UNK DIAGNOSIS) Gastrointestinal disorder (04AUG2014)	Related Not Related IB Recovered/resolved (02SEP2014)
	2 DOXORUBICIN	Unknown --x90mg / -- --	19JUN2014/ --			
	3 CYCLOPHOSPHAMIDE	Unknown --	19JUN2014/ --			
	4 VINCRISTINE	Unknown --	19JUN2014/ --			
	5 PREDNISONE	Unknown --	19JUN2014/ --			

Indication: MANTLE CELL LYMPHOMA STAGE IV - SUSARs to non-company IMPs

NO SUSARS WERE IDENTIFIED

RITUXIMAB

Indication: NON-HODGKIN'S LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
ML21685 1436496(0.0) 2008-005859-16 159 72195 GERMANY 60 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x600mg / 4 Weeks	07AUG2013/ --		PROMYELOCYTIC LEUKAEMIA Acute promyelocytic leukaemia (20JUN2014)	Related Related EU-SPC Not recovered/not resolved
	2 BENDAMUSTINE	Intravenous (not otherwise specified) 1x280mg / 4 Weeks	07AUG2013/ --			

Indication: NON-HODGKIN'S LYMPHOMA - SUSARs to non-company IMPs

NO SUSARS WERE IDENTIFIED

RITUXIMAB

Indication: NON-HODGKIN'S LYMPHOMA UNSPECIFIED HISTOLOGY INDOLENT - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
BO21223 1052236(4.0) 2010-024132-41 209358 56552 GERMANY 66 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x---- / 3 Weeks	24NOV2011/ --	Neutropenia Vomiting Constipation Umbilical hernia	COMPRESSION FRACTURE Compression fracture (14APR2012)	Related Related EU-SPC Recovered/resolved (18APR2012)
	2 CYCLOPHOSPHAMIDE	Intravenous (not otherwise specified) 1x---- / 3 Weeks	24NOV2011/ --			
	3 DOXORUBICIN	Intravenous (not otherwise specified) 1x---- / 3 Weeks	24NOV2011/ --			
	4 VINCRISTINE	Intravenous bolus 1x---- / 3 Weeks	-- --			
	5 PREDNISONE	Oral 1x---- / 3 Weeks	24NOV2011/ --			

RITUXIMAB

Indication: NON-HODGKIN'S LYMPHOMA UNSPECIFIED HISTOLOGY INDOLENT - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
BO21223 1391147(2.0) 2010-024132-41 255266 59054 CHINA 64 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x---- / 2 Months	29JUL2013/ --	Irritability Liver injury Neutropenia Leukopenia	CARCINOMA OF COLON Colon cancer (24APR2014)	Related Related EU-SPC Not recovered/not resolved
	2 CYCLOPHOSPHAMIDE	Intravenous (not otherwise specified) 1x---- / 3 Weeks	30JUL2013/ --			
	3 DOXORUBICIN	Intravenous (not otherwise specified) 1x---- / 3 Weeks	30JUL2013/ --			
	4 VINCRISTINE	Intravenous bolus 1x---- / 3 Weeks	-- --			
	5 PREDNISOLONE	Oral 1x---- / 3 Weeks	29JUL2013/ --			

Indication: NON-HODGKIN'S LYMPHOMA UNSPECIFIED HISTOLOGY INDOLENT - SUSARs to non-company IMPs

NO SUSARS WERE IDENTIFIED

RITUXIMAB

Indication: RHEUMATOID ARTHRITIS - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
ML20580 1423635(2.0) 2009-015950-39 107189 11612153 GERMANY 65 Years Female	**1 # RITUXIMAB** **(Blinded)**	Intravenous (not otherwise specified) -- Intravenous (not otherwise specified) --	02JAN2014/ -- 16JAN2014/ --	Hyperuricaemia Hypertension	SUSPECT FINDING IN PANCREAS (ENLARGEMENT OF PANCREAS DUCTUS) Pancreatic enlargement (18JUN2014) PANCREATITIS Pancreatitis (02JUL2014)	Related Not Related EU-SPC Recovered/resolved (02JUL2014) Related Not Related EU-SPC Recovered/resolved (09JUL2014)

Indication: RHEUMATOID ARTHRITIS - SUSARs to non-company IMPs

NO SUSARS WERE IDENTIFIED

Dataset Parameters	
Dataset Name	17NOV2014_SSR_1062347
Date range (Informed Date)	from 26MAY2014 to 17NOV2014
Report Parameters	
SSR Drug	RITUXIMAB (FORM UNKNOWN);RITUXIMAB (IV);RITUXIMAB (SC)
Unblinded Report?	No

Current MedDRA Version: v.17.1

Report ID: SSR02 v1.1.1.0